Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose safety, tolerability, and pharmacokinetics of MK-8690 in healthy Japanese adults
jRCT2051250077Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of aprepitant in autoimmune colitis (5 arms), sponsored by Merck & Co. Primary endpoint: Adverse events. Started Sep 2025; status: completed.
02
Drugs
aprepitant
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on jRCT2051250077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051250077.